Skip to main
ALT
ALT logo

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. has demonstrated promising clinical results for its investigational drug pemvidutide, showcasing weight loss of up to 6.2% over 24 weeks and significant liver fat reduction of 62.8%, alongside compelling anti-fibrotic activity indicated by improvements in biomarker and histological measures. The recent positive developments in the metabolic dysfunction field, highlighted by Novo's acquisition of Akero Therapeutics, underscore a growing market for treatments like pemvidutide that may offer a simplified approach to metabolic diseases without the complexities of combination therapies. Furthermore, the strengthening of Altimmune’s leadership team in preparation for upcoming pivotal trials enhances confidence in pemvidutide’s potential as a best-in-class therapy for obesity and metabolic-associated steatohepatitis (MASH).

Bears say

Altimmune Inc has experienced a significant decline in its stock price, falling approximately 55%, despite the development of its promising product candidate, pemvidutide. The company's outlook is marred by numerous risks associated with clinical development, competition, commercialization, and reimbursement, among others, which cumulatively contribute to a cautious financial perspective. Furthermore, potential disruptions from external factors such as COVID-19 and geopolitical tensions in Eastern Europe may further complicate clinical trial timelines and overall business operations, heightening the uncertainty surrounding Altimmune's future market performance.

Altimmune (ALT) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Altimmune (ALT) has a Strong Buy consensus rating as of Nov 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.